[ad_1]
For the quarter ended September 2023, Ashland (ASH) reported revenue of $518 million, down 17.9% over the same period last year. EPS came in at $0.41, compared to $1.46 in the year-ago quarter.
The reported revenue represents a surprise of +0.01% over the Zacks Consensus Estimate of $517.97 million. With the consensus EPS estimate being $0.47, the EPS surprise was -12.77%.
While investors closely watch year-over-year changes in headline numbers — revenue and earnings — and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company’s underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock’s price performance more accurately.
Here is how Ashland performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Intermediates: $37 million versus the four-analyst average estimate of $40.36 million. The reported number represents a year-over-year change of -42.2%.
- Revenue- Life Sciences: $203 million versus the four-analyst average estimate of $206.58 million. The reported number represents a year-over-year change of -4.7%.
- Revenue- Personal Care: $146 million compared to the $150.41 million average estimate based on four analysts. The reported number represents a change of -22.3% year over year.
- Revenue- Specialty Additives: $144 million compared to the $150.06 million average estimate based on four analysts. The reported number represents a change of -23% year over year.
- Revenue- Intersegment sales: -$12 million compared to the -$17.68 million average estimate based on two analysts. The reported number represents a change of -42.9% year over year.
- Adjusted EBITDA- Personal Care: $36 million versus the four-analyst average estimate of $27.75 million.
- Adjusted EBITDA- Specialty Additives: $8 million versus $21 million estimated by four analysts on average.
- Adjusted EBITDA- Life Science: $48 million versus $51.76 million estimated by four analysts on average.
- Adjusted EBITDA- Intermediates: $3 million versus $11.59 million estimated by four analysts on average.
View all Key Company Metrics for Ashland here>>>
Shares of Ashland have returned -3% over the past month versus the Zacks S&P 500 composite’s +1.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Ashland Inc. (ASH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
[ad_2]
Source link
